Program
Cytarabine
Also written as “cytarabine”, “Liposomal Annamycin Injection in combination with Cytarabine Injection” and “Cytarabine (Ara-C)”.
Its studies are mostly in Leukemia, Myeloid, Acute · Leukemia · Lymphoma · Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Mesothelioma, Malignant, led by 23 companies.
Drug pageCytarabine: every studyMany companies study it; this page follows only the 32 they lead. All 497 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartisits history only | 30 open or running | phase 3since Oct 4, 2000 | Oct 4, 2000 | none ahead |
| Vion Pharmaceuticalsits history only | 30 open or running | phase 2since Jul 19, 2006 | Jul 8, 2003 | none ahead |
| Antisoma Researchits history only | 20 open or running | phase 3since Jul 14, 2008 | Jul 14, 2008 | none ahead |
| Boehringer Ingelheimits history only | 20 open or running | phase 2since Mar 4, 2008 | Mar 4, 2008 | none ahead |
| Hoffmann-La Rocheits history only | 20 open or running | phase 2since Aug 16, 2007 | Aug 16, 2007 | none ahead |
| Moleculin Biotechits history only | 21 open or running | phase 3since Dec 5, 2024 | Feb 22, 2022 | Aug 2029phase 3 · NCT06788756 |
| Theradexits history only | 20 open or running | phase 2since Oct 3, 2003 | Jan 27, 2003 | none ahead |
| AbbVieits history only | 10 open or running | phase 3since Aug 10, 2020 | Aug 10, 2020 | none ahead |
| Arog Pharmaceuticalsits history only | 10 open or running | phase 2since Oct 18, 2017 | Oct 18, 2017 | none ahead |
| Cornerstone Pharmaceuticalsits history only | 10 open or running | phase 3since Apr 12, 2018 | Apr 12, 2018 | none ahead |
| CSPC Pharmaceutical Groupits history only | 10 open or running | phase 2since Oct 19, 2021 | Oct 19, 2021 | none ahead |
| Eleosits history only | 10 open or running | phase 2since Dec 19, 2003 | Dec 19, 2003 | none ahead |
| Kanisa Pharmaceuticalsits history only | 10 open or running | phase 2since Aug 9, 2005 | Aug 9, 2005 | none ahead |
| Kura Oncologyits history only | 11 open or running | phase 3since May 16, 2025 | May 16, 2025 | Nov 2031phase 3 · NCT07007312 |
| Oncovirits history only | 10 open or running | phase 1since Aug 19, 2020 | Aug 19, 2020 | none ahead |
| Pfizerits history only | 10 open or running | phase 3since Dec 21, 2017 | Dec 21, 2017 | none ahead |
| Polaris Groupits history only | 10 open or running | phase 1since Aug 9, 2016 | Aug 9, 2016 | none ahead |
| Sichuan Biokin Pharmaceuticalits history only | 11 open or running | phase 3since Nov 20, 2025 | Nov 20, 2025 | Dec 2027phase 3 · NCT07255872 |
| Stelexis BioSciencesits history only | 11 open or running | phase 1since Jul 24, 2024 | Jul 24, 2024 | Dec 15, 2027phase 1 · NCT06533761 |
| Sumitomo Pharmaits history only | 10 open or running | phase 1since Sep 27, 2017 | Sep 27, 2017 | none ahead |
| Tarapeutics Scienceits history only | 11 open or running | phase 2since Jan 16, 2022 | Jan 16, 2022 | none ahead |
| Texas Oncology Cancer Centerits history only | 10 open or running | phase 2since Nov 18, 2011 | Nov 18, 2011 | none ahead |
| Xanthus Pharmaceuticalsits history only | 10 open or running | phase 2since Jan 5, 2006 | Jan 5, 2006 | none ahead |
Also a collaborator on its studies: Baili-Bio (Chengdu) Pharmaceutical.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 18 studies since Oct 4, 2000.
- Aug 9, 2016Polaris Group’s first study: phase 1 study in Leukemia, Myeloid, AcuteNew to Polaris GroupPolaris Group · NCT02875093 · 23 enrolled · Taiwan
- Sep 27, 2017Sumitomo Pharma’s first study: phase 1 study in Leukemia, Myeloid, AcuteNew to Sumitomo PharmaSumitomo Pharma · NCT03298984 · 32 enrolled · United States
- Oct 18, 2017Arog Pharmaceuticals’ first study: phase 2 study in RecurrenceNew to Arog PharmaceuticalsArog Pharmaceuticals · NCT03324243
- Dec 21, 2017Pfizer’s first study: phase 3 study in Leukemia, Myeloid, AcuteNew to PfizerPfizer · NCT03416179 · 730 enrolled · United States, Australia, Austria and more
- Apr 12, 2018Cornerstone Pharmaceuticals’ first study: phase 3 study in Leukemia, Myeloid, AcuteNew to Cornerstone PharmaceuticalsCornerstone Pharmaceuticals · NCT03504410 · 200 enrolled · United States, Australia, Austria and more
- Aug 10, 2020AbbVie’s first study: phase 3 study in Leukemia, Myeloid, AcuteNew to AbbVieAbbVie · NCT04509622 · 14 enrolled · Japan
- Aug 19, 2020Oncovir’s first study: phase 1 study in Mesothelioma, MalignantNew to OncovirOncovir · NCT04525859 · 19 enrolled · United States
- Oct 19, 2021CSPC Pharmaceutical Group’s first study: phase 2 study in RecurrenceNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT05100303 · 58 enrolled · China
- Jan 16, 2022Tarapeutics Science’s first study: phase 2 study in RecurrenceNew to Tarapeutics ScienceTarapeutics Science · NCT05241093 · 18 planned · China
- Feb 22, 2022Moleculin Biotech’s first study: phase 2 study in Leukemia, Myeloid, AcuteNew to Moleculin BiotechMoleculin Biotech · NCT05319587 · 22 enrolled · Italy, Poland
- Jul 24, 2024Stelexis BioSciences’ first study: phase 1 study in Leukemia, Myeloid, AcuteNew to Stelexis BioSciencesStelexis BioSciences · NCT06533761 · 105 planned · United States, Spain
- Dec 5, 2024Phase 3 study in Leukemia, Myeloid, AcuteMoleculin Biotech · NCT06788756 · 312 planned · United States, Czechia, Georgia and more
- May 16, 2025Kura Oncology’s first study: phase 3 study in Leukemia, Myeloid, AcuteNew to Kura OncologyKura Oncology · NCT07007312 · 1,300 planned · United States, Australia, Belgium and more
- Nov 20, 2025Sichuan Biokin Pharmaceutical’s first study: phase 3 study in Leukemia, Myeloid, AcuteNew to Sichuan Biokin PharmaceuticalSichuan Biokin Pharmaceutical · NCT07255872 · 216 planned · China
Ahead
- Dec 2027Primary completion: phase 3 study in Leukemia, Myeloid, AcuteSichuan Biokin Pharmaceutical · NCT07255872
- Dec 15, 2027Primary completion: phase 1 study in Leukemia, Myeloid, AcuteStelexis BioSciences · NCT06533761
- Aug 2029Primary completion: phase 3 study in Leukemia, Myeloid, AcuteMoleculin Biotech · NCT06788756
- Nov 2031Primary completion: phase 3 study in Leukemia, Myeloid, AcuteKura Oncology · NCT07007312
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 32 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07255872Leukemia, Myeloid, Acute · China | 3 | Recruiting | Sichuan Biokin Pharmaceutical | Dec 2027 | 216 |
| NCT07007312Leukemia, Myeloid, Acute · United States, Australia, Belgium and more | 3 | Recruiting | Kura Oncology | Nov 2031 | 1,300 |
| NCT06788756Leukemia, Myeloid, Acute · United States, Czechia, Georgia and more | 3 | Recruiting | Moleculin Biotech | Aug 2029 | 312 |
| NCT06533761Leukemia, Myeloid, Acute · United States, Spain | 1 | Recruiting | Stelexis BioSciences | Dec 15, 2027 | 105 |
| NCT05319587Leukemia, Myeloid, Acute · Italy, Poland | 2 | Completed | Moleculin Biotech | Aug 2, 2023 | 22 |
| NCT05241093Recurrence · China | 2 | Recruiting | Tarapeutics Science | Dec 30, 2025 | 18 |
| NCT05100303Recurrence · China | 2 | UNKNOWN | CSPC Pharmaceutical Group | Nov 2022 | 58 |
| NCT04525859Mesothelioma, Malignant · United States | 1 | Completed | Oncovir | Jun 18, 2025 | 19 |
| NCT04509622Leukemia, Myeloid, Acute · Japan | 3 | Completed | AbbVie | Apr 15, 2021 | 14 |
| NCT03504410Leukemia, Myeloid, Acute · United States, Australia, Austria and more | 3 | Terminated | Cornerstone Pharmaceuticals | Oct 25, 2021 | 200 |
| NCT03416179Leukemia, Myeloid, Acute · United States, Australia, Austria and more | 3 | Completed | Pfizer | Jun 5, 2020 | 730 |
| NCT03324243Recurrence | 2 | Withdrawn | Arog Pharmaceuticals | Dec 2020 | 0 |
| NCT03298984Leukemia, Myeloid, Acute · United States | 1 | Completed | Sumitomo Pharma | Mar 20, 2020 | 32 |
| NCT02875093Leukemia, Myeloid, Acute · Taiwan | 1 | Terminated | Polaris Group | Jul 10, 2019 | 23 |
| NCT01773408Leukemia, Myeloid, Acute · United States, Australia, Canada and more | 1 | Completed | Hoffmann-La Roche | Jun 2016 | 122 |
| NCT01500161Leukemia, Myeloid, Acute · United States | 2 | Terminated | Texas Oncology Cancer Center | Nov 2013 | 1 |
| NCT01066494Leukemia, Myeloid, Acute · Georgia, Ukraine | 2 | UNKNOWN | Antisoma Research | Sep 2010 | 20 |
| NCT00804856Leukemia, Myeloid, Acute · Austria, Belgium, Canada and more | 2 | Completed | Boehringer Ingelheim | Mar 9, 2012 | 180 |
| NCT00715637Leukemia · United States, Argentina, Australia and more | 3 | UNKNOWN | Antisoma Research | Jun 2010 | 420 |
| NCT00632749Leukemia, Myeloid, Acute · Germany | 2 | Completed | Boehringer Ingelheim | Mar 2014 | 68 |
| NCT00517699Lymphoma · Canada | 2 | Terminated | Hoffmann-La Roche | Mar 2009 | 5 |
| NCT00354276Leukemia · United States, France, United Kingdom | 2 | UNKNOWN | Vion Pharmaceuticals | Dec 2008 | 85 |
| NCT00333840Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Australia, Austria and more | 3 | Completed | Novartis | Mar 2012 | 1,106 |
| NCT00273884Leukemia, Myeloid, Acute · United States, Canada | 2 | Completed | Xanthus Pharmaceuticals | 80 | |
| NCT00129168Leukemia, Myeloid | 2 | Completed | Kanisa Pharmaceuticals | Mar 2008 | 100 |
| NCT00093600Leukemia, Myeloid, Acute · United States, Germany | 1 | Completed | Novartis | Jun 2011 | 69 |
| NCT00074737Leukemia, Myeloid, Acute · United States | 2 | Completed | Eleos | May 2007 | 53 |
| NCT00070538Leukemia · United States | 1 | Completed | Vion Pharmaceuticals | Sep 2004 | |
| NCT00069966Lymphoma · United States, Puerto Rico | 2 | UNKNOWN | Theradex | ||
| NCT00064090Leukemia · United States | 1 | Completed | Vion Pharmaceuticals | Sep 2004 | |
| NCT00053105Lymphoma · United States | 1 | UNKNOWN | Theradex | ||
| NCT00006343Leukemia · United States | 3 | Completed | Novartis | Mar 2007 |
How it is read
Names in the registry
- “Cytarabine”, 15 entries
- “cytarabine”, 8 entries
- “Liposomal Annamycin Injection in combination with Cytarabine Injection”, 2 entries
- “Cytarabine (Ara-C)”, 1 entry
- “Eganelisib in combination with cytarabine”, 1 entry
Conditions, from the studies’ own filings
- Leukemia, Myeloid, Acute, 22 studies
- Leukemia, 3 studies
- Lymphoma, 2 studies
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive, 2 studies
- Mesothelioma, Malignant, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.